imatinib mesylate has been researched along with Coronary Artery Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Accurso, V; Badalamenti, G; Bronte, E; Di Lisi, D; Macaione, F; Novo, G; Novo, S; Rinaldi, G; Russo, A; Siragusa, S | 1 |
| Ikemura, M; Ishihara, S; Kanazawa, T; Kitayama, J; Komuro, I; Nozawa, H; Sunami, E; Takahashi, M; Tanaka, T; Watanabe, T | 1 |
| Balsat, M; Bert, A; Blond, E; Drai, J; Escoffre-Barbe, M; Etienne, G; Etienne, M; Fossard, G; Giraudier, S; Heiblig, M; Labussière-Wallet, H; Lega, JC; Mahon, FX; Morisset, S; Nicolini, FE; Redonnet-Vernhet, I; Sobh, M | 1 |
| Letendre, L; Tefferi, A | 1 |
| Gambacorti-Passerini, C; Piazza, R | 1 |
| Dörken, B; Fateh-Moghadam, S; Giles, FJ; Grille, P; Haverkamp, W; Kim, TD; Köhncke, C; le Coutre, P; Levitin, M; Schwarz, M | 1 |
| Aaltola, EM; Buchdunger, E; Koskinen, PK; Krebs, R; Laitinen, O; Lemström, KB; Sihvola, RK; Tikkanen, JM | 1 |
7 other study(ies) available for imatinib mesylate and Coronary Artery Disease
| Article | Year |
|---|---|
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Topics: Aged; Coronary Artery Disease; Dasatinib; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pulse Wave Analysis; Pyridazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2020 |
Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy.
Topics: Aged; Anal Canal; Anticoagulants; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Neoadjuvant Therapy; Organ Sparing Treatments; Piperazines; Pyrimidines; Rectal Neoplasms; Treatment Outcome | 2014 |
Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Cholesterol, HDL; Coronary Artery Disease; Drug Administration Schedule; Female; Homocysteine; Humans; Hyperhomocysteinemia; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prospective Studies; Pyrimidines; Retrospective Studies; Triglycerides | 2016 |
Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.
Topics: Benzamides; Coronary Artery Disease; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
Topics: Adult; Aged; Benzamides; Blood Glucose; Cohort Studies; Constriction, Pathologic; Coronary Artery Disease; Drug Resistance, Neoplasm; Fasting; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Clinical cardiac safety profile of nilotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Coronary Artery Disease; Electrocardiography; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Heart; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Ventricular Function, Left | 2012 |
Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits.
Topics: Animals; Antineoplastic Agents; Aorta, Thoracic; Aortic Diseases; Benzamides; Cholesterol, Dietary; Coronary Artery Disease; Female; Graft Survival; Heart Transplantation; Hypercholesterolemia; Imatinib Mesylate; Incidence; Macrophages; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Rabbits; Receptors, Platelet-Derived Growth Factor; Transplantation, Homologous | 2003 |